Myasthenia Gravis Treatment Market Analysis by Treatment (Surgery, Medication, Others), by End User (Hospitals, Clinics, Others), and by Region - Forecast to 2029

The global myasthenia gravis treatment market size is estimated to be USD 1,621.5 million in 2020 and is expected to witness a CAGR of 7.81% during the forecast period. Increasing number of clinical trials for treatment is a key driver for the growth of the global myasthenia gravis treatment market. Additionally, consistent research and development activities, growing investment by various private players, and progress of technologically advanced drugs are some of the other drivers propelling the market growth. Nevertheless, side effects of drugs used in the treatment of myasthenia gravis and high cost of tools and technologies are expected to restrain the global market growth.

Global Myasthenia Gravis Treatment Market Size (USD Million), 2021-2029

Source: Erevna Healthcare

By Treatment

Based on treatment, the market is segmented into surgery, medication, and others. In 2020, the medication treatment segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the fact that medications can radically inhibit the immune system and aid in the management of the associated symptoms. Surgery segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to an increase in the number of patients visiting the hospitals due to the accessibility of a wide range of treatment options in such facilities.

By End User

Based on end user, the market is segmented into clinics, hospitals, and others. In 2020, the hospital segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to a large number of patients and high demand for advanced technologies for myasthenia gravis treatment in hospital settings worldwide. The clinics segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to increase in number of patients visiting the clinics of myasthenia gravis due to the availability of a wide range of treatment options in such facilities.

Regional Insights

In 2020, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the high rate of adoption of immunotherapies and monoclonal antibodies, increase in healthcare expenditure, and existence of established research and development facilities. Asia Pacific market is projected to grow at the fastest rate over the forecast period owing to the presence of the large population base and future growth opportunities in this region as major pharmaceutical players are willing to invest in this region.

Competitor Insights

Some of the major companies in the myasthenia gravis treatment market Alexion Pharmaceutical Inc. (U.S.), Grifols SA (Spain), Avadel Pharmaceuticals plc. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (U.K.), Bausch Health Companies Inc. (Canada), and Shire plc (U.S.). Investment in R&D, novel product launches, and strategic collaborations & acquisitions are some of the major strategies adopted by the leading players operating in the industry.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The myasthenia gravis treatment market report is categorized into the following segments and subsegments:

Myasthenia Gravis Treatment Market, By Treatment (Revenue, 2021-2029, USD Million)

  • Surgery Market
  • Medication Market
  • Others Market

Myasthenia Gravis Treatment Market, By End User (Revenue, 2021-2029, USD Million)

  • Clinics Market
  • Hospitals Market
  • Others Market

Myasthenia Gravis Treatment Market, By Region (Revenue, 2021-2029, USD Million)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Scope of Myasthenia Gravis Treatment Market Report:

Key Parameters Details
Base Year
  • 2021
Forecast Period
  • 2022-2029
Study Coverage
  • Global and regional market size and revenue forecast
  • Segment market size and revenue forecast at global, regional, and country level
  • Competitive landscape (company share analysis, company profiles, recent development, competitive map analysis)
  • Conclusion and recommendations
Qualitative Analysis
  • Market drivers
  • Market restraints
  • Market opportunities
  • Recent market trends
  • Market challenges
  • Porter’s Five Forces analysis
  • PEST analysis
  • Value-chain analysis
  • COVID-19 impact analysis
Regional Market Scope
  • North America (U.S. and Canada)
  • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
  • MEA (South Africa, GCC, Rest of MEA)
Company Profiles
  • Exhaustive profiles of top 15 players
  • 50+ other major players listing
15% Free Customization Available
  • You can customize the study scope to meet your exact requirement. Click here for more details

Table of Contents: Myasthenia Gravis Treatment Market 2021-2029

  1. Research Methodology
    1. Study Objectives
    2. Study Scope
    3. Research Assumptions
    4. Research Framework
      1. Research Models
        1. Bottom-up Approach
        2. Top-down Approach
        3. Data Triangulation
      2. Data Procurement
        1. Internal Database
        2. Secondary Research
        3. Purchased Database
        4. Primary Research
      3. Data Analysis
        1. Data Validation
        2. Market Size Estimation
        3. Market Forecast Model
      4. Quality Assessment
  1. Introduction: Myasthenia Gravis Treatment
  2. Executive Summary
    1. Global Market Scenario
    2. Segment Market Scenario
    3. Geographic Market Scenario
    4. COVID-19 Impact
    5. Competitive Landscape
  3. Market Dynamics
    1. Market Drivers
      1. Driver 1
      2. Driver 2
      3. Driver 3
      4. Driver 4
      5. Driver 5
    2. Market Restraint
      1. Restraint 1
      2. Restraint 2
      3. Restraint 3
      4. Restraint 4
    3. Market Opportunities
      1. Opportunity 1
      2. Opportunity 2
      3. Opportunity 3
      4. Opportunity 4
    4. Market Trends
      1. Trend 1
      2. Trend 2
      3. Trend 3
      4. Trend 4
    5. Market Challenges
      1. Challenge 1
      2. Challenge 2
      3. Challenge 3
      4. Challenge 4
  1. Market Environment Analysis
    1. Porter’s 5 Forces Analysis
    2. PESTEL Analysis
    3. Value Chain Analysis
    4. SWOT Analysis
    5. Benchmark
  2. COVID-19 Impact Analysis: Myasthenia Gravis Treatment Market
    1. COVID-19: Overview
    2. COVID-19 Impact on the Global Market
    3. COVID-19 Impact on the Regional Markets
  3. Market Analysis by Treatment
    1. Surgery Market
      1. Surgery Market Market Forecast, 2021-2029 (USD Million)
    2. Medication Market
      1. Medication Market Market Forecast, 2021-2029 (USD Million)
    3. Others Market
      1. Others Market Market Forecast, 2021-2029 (USD Million)
  1. Market Analysis by End User
    1. Clinics Market
      1. Clinics Market Market Forecast, 2021-2029 (USD Million)
    2. Hospitals Market
      1. Hospitals Market Market Forecast, 2021-2029 (USD Million)
    3. Others Market
      1. Others Market Market Forecast, 2021-2029 (USD Million)
  1. Regional Market Analysis
    1. Regional Market Trends
    2. Regional Market: Comparative Analysis
  2. North America Myasthenia Gravis Treatment Market
    1. North America Myasthenia Gravis Treatment Market
      1. North America Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
        2. Market Size and Forecast by End User, 2021-2029 (USD Million)
      2. S. Myasthenia Gravis Treatment Market
        1. S. Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
          2. Market Size and Forecast by End User, 2021-2029 (USD Million)
        2. Canada Myasthenia Gravis Treatment Market
          1. Canada Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
            2. Market Size and Forecast by End User, 2021-2029 (USD Million)
  1. Europe Myasthenia Gravis Treatment Market
    1. Europe Myasthenia Gravis Treatment Market
      1. Europe Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
        2. Market Size and Forecast by End User, 2021-2029 (USD Million)
      2. Germany Myasthenia Gravis Treatment Market
        1. Germany Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
          2. Market Size and Forecast by End User, 2021-2029 (USD Million)
        2. UK Myasthenia Gravis Treatment Market
          1. UK Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
            2. Market Size and Forecast by End User, 2021-2029 (USD Million)
          2. France Myasthenia Gravis Treatment Market
            1. France Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
              2. Market Size and Forecast by End User, 2021-2029 (USD Million)
            2. Spain Myasthenia Gravis Treatment Market
              1. Spain Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
                2. Market Size and Forecast by End User, 2021-2029 (USD Million)
              2. Italy Myasthenia Gravis Treatment Market
                1. Italy Market Size and Forecast, 2021-2029 (USD Million)
                  1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
                  2. Market Size and Forecast by End User, 2021-2029 (USD Million)
                2. Rest of Europe Myasthenia Gravis Treatment Market
                  1. Rest of Europe Market Size and Forecast, 2021-2029 (USD Million)
                    1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
                    2. Market Size and Forecast by End User, 2021-2029 (USD Million)
  1. Asia Pacific Myasthenia Gravis Treatment Market
    1. Asia Pacific Myasthenia Gravis Treatment Market
      1. Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
        2. Market Size and Forecast by End User, 2021-2029 (USD Million)
      2. Japan Myasthenia Gravis Treatment Market
        1. Japan Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
          2. Market Size and Forecast by End User, 2021-2029 (USD Million)
        2. China Myasthenia Gravis Treatment Market
          1. China Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
            2. Market Size and Forecast by End User, 2021-2029 (USD Million)
          2. India Myasthenia Gravis Treatment Market
            1. India Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
              2. Market Size and Forecast by End User, 2021-2029 (USD Million)
            2. South Korea Myasthenia Gravis Treatment Market
              1. South Korea Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
                2. Market Size and Forecast by End User, 2021-2029 (USD Million)
                3. Market Size and Forecast by Device, 2021-2029 (USD Million)
              2. Australia Myasthenia Gravis Treatment Market
                1. Australia Market Size and Forecast, 2021-2029 (USD Million)
                  1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
                  2. Market Size and Forecast by End User, 2021-2029 (USD Million)
                2. Rest of Asia Pacific Myasthenia Gravis Treatment Market
                  1. Rest of Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
                    1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
                    2. Market Size and Forecast by End User, 2021-2029 (USD Million)
  1. Latin America Myasthenia Gravis Treatment Market
    1. Latin America Myasthenia Gravis Treatment Market
      1. Latin America Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
        2. Market Size and Forecast by End User, 2021-2029 (USD Million)
      2. Brazil Myasthenia Gravis Treatment Market
        1. Brazil Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
          2. Market Size and Forecast by End User, 2021-2029 (USD Million)
        2. Mexico Myasthenia Gravis Treatment Market
          1. Mexico Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
            2. Market Size and Forecast by End User, 2021-2029 (USD Million)
          2. Argentina Myasthenia Gravis Treatment Market
            1. Argentina Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
              2. Market Size and Forecast by End User, 2021-2029 (USD Million)
            2. Rest of Latin America Myasthenia Gravis Treatment Market
              1. Rest of Latin America Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
                2. Market Size and Forecast by End User, 2021-2029 (USD Million)
  1. MEA Myasthenia Gravis Treatment Market
    1. MEA Myasthenia Gravis Treatment Market
      1. MEA Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
        2. Market Size and Forecast by End User, 2021-2029 (USD Million)
      2. GCC Myasthenia Gravis Treatment Market
        1. GCC Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
          2. Market Size and Forecast by End User, 2021-2029 (USD Million)
        2. South Africa Myasthenia Gravis Treatment Market
          1. South Africa Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
            2. Market Size and Forecast by End User, 2021-2029 (USD Million)
          2. Rest of MEA Myasthenia Gravis Treatment Market
            1. Rest of MEA Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Treatment, 2021-2029 (USD Million)
              2. Market Size and Forecast by End User, 2021-2029 (USD Million)
  1. Competitor Analysis
    1. Market Share Analysis, 2021 & 2029
    2. Competitive Mapping
    3. Key Players Market Place Analysis
    4. Major Recent Developments
  2. Company Profiles
    1. Alexion Pharmaceutical Inc. (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    2. Grifols SA (Spain)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    3. Avadel Pharmaceuticals plc. (France)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    4. Novartis AG (Switzerland)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    5. Pfizer Inc. (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    6. AbbVie Inc. (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    7. Hoffmann-La Roche Ltd. (Switzerland)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    8. GlaxoSmithKline plc (U.K.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    9. Bausch Health Companies Inc. (Canada)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    10. Shire plc (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    11. Company 11
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    12. Company 12
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    13. Company 13
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    14. Company 14
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    15. Company 15
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Treatment Benchmarking
      5. Recent Developments
    16. Others Prominent Players

Conclusion & Recommendations

Select License Type

7 Reasons to Choose EHMR Reports

  • Customer’s Satisfaction

    First and foremost client’s satisfaction, which is very important for Erevna Healthcare and we are committed towards it

  • Client Report

    Customised reports

    Expert in healthcare domain and in depth insights on the report. Erevna Healthcare also customise reports as per the client’s requirement

  • Analyst Support

    Experienced team of analysts with strong background in Pharma, Life Sciences and Biotechnology

  • Assured Quality

    Each report passes through three tiers of quality check

  • Stick to the timeline

    Stick to the timeline

    Erevna Healthcare analysts stick to the timeline

  • Quick delivery

    Quick delivery of reports as per client’s request in three different forms i.e. pdf, ppt and word

  • 24x7 Supprt

    24*7 Support

    24*7 Support post delivery/dispatch of all the reports